Clinical trials: Schizo Affective Disorder
Schizophrenia, Schizoaffective Disorder
Artemisinin to Reduce The Symptoms of Schizophrenia
The investigators intend to explore the hypothesis that symptoms of schizophrenia may be reduced by the antimalarial compound artemisinin when used in addition to standard antipsychotic medications.
- Trial name
- NCT00753506
- Testing
- Artemisinin
- Where
- United States
- Volunteers
- 66 people
- Sponsor
- Sheppard Pratt Health System
Schizophrenia, Schizoaffective Disorder
Varenicline Adjunctive Treatment in Schizophrenia
The principal aim of the project is to conduct an off-label adjunctive clinical trial evaluating varenicline as a treatment for core neurobiological and clinical deficits in schizophrenia, in addition to evaluating for smoking…
- Conditions
- Schizophrenia, Schizoaffective Disorder, Schizophreniform Disorder
- Trial name
- NCT00492349
- Testing
- Varenicline
- Where
- 3 sites in United States
- Volunteers
- 91 people
- Sponsor
- University of Maryland, Baltimore
Schizophrenia, Schizoaffective Disorder
Ramelteon as an Adjunct Therapy in Non-Diabetic Patients With Schizophrenia
This study involves people who have schizophrenia or schizoaffective disorder who are currently taking antipsychotic medications.
- Conditions
- Schizophrenia, Schizoaffective Disorder, Schizophreniform Disorders
- Trial name
- NCT00595504
- Testing
- Ramelteon
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- Massachusetts General Hospital
Schizophrenia, Schizo Affective Disorder
iTEST: Introspective Accuracy as a Novel Target for Functioning in Psychotic Disorders
People with psychotic disorders experience a high level of functional disability, and a major contributor to this disability is introspective accuracy, which is defined as inaccurate judgements of one's abilities and performance…
- Conditions
- Schizophrenia, Schizo Affective Disorder, Psychotic Disorders
- Trial name
- iTEST (NCT05899348)
- Testing
- iTEST
- Where
- 2 sites in United States
- Volunteers
- 69 people
- Sponsor
- University of California, San Diego
Schizophrenia, Schizoaffective Disorder
Trial Comparing the Effects of Aripiprazole With Those of Standard of Care on Non-HDL Cholesterol in Patients With Schizophrenia or Bipolar I Disorder Who Have Metabolic Syndrome
The purpose of this study was to determine whether patients with schizophrenia, schizoaffective disorder, or bipolar I disorder who also have metabolic syndrome have a larger decrease in fasting non-high density lipoprotein…
- Conditions
- Schizophrenia, Schizoaffective Disorder, Bipolar I Disorder, Metabolic Syndrome
- Trial name
- NCT00857818
- Testing
- Aripiprazole, Oanzapine, risperidone, or quetiapine
- Where
- 14 sites in Canada
- Volunteers
- 64 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Schizophrenia, Negative Type; Schizophrenic
Using Transcranial Magnetic Stimulation (TMS) to Understand 'Negative' Symptoms of Schizophrenia
The main purpose of this study is to learn how transcranial magnetic stimulation (TMS) helps improve negative symptoms of schizophrenia.
- Conditions
- Schizophrenia, Negative Type; Schizophrenic, Schizo Affective Disorder
- Trial name
- NCT03648268
- Testing
- repetitive Transcranial Magnetic Stimulation (rTMS)
- Where
- United States
- Volunteers
- 47 people
- Sponsor
- Beth Israel Deaconess Medical Center
Schizophrenia, Schizoaffective Disorder
A Comparison of Long-acting Injectable Medications for Schizophrenia
The purpose of this research study is to compare the "real-world" effectiveness of two FDA-approved and widely used long-acting injectable antipsychotic medications (paliperidone palmitate and haloperidol decanoate) in patients…
- Trial name
- ACLAIMS (NCT01136772)
- Testing
- haloperidol decanoate, paliperidone palmitate
- Where
- 22 sites in United States
- Volunteers
- 311 people
- Sponsor
- New York State Psychiatric Institute
Schizophrenia, Schizoaffective Disorder
Lurasidone HCl - A Long Term Safety Phase 3 Study of Patients With Clinically Stable Schizophrenia
Lurasidone HCl is a compound being developed for the treatment of schizophrenia. This clinical study is designed to test the hypothesis that lurasidone is safe and tolerable long term among clinically stable patients.
- Trial name
- NCT00641745
- Testing
- Lurasidone HCl, Risperidone
- Where
- 73 sites in United States, Argentina and 6 more
- Volunteers
- 629 people
- Sponsor
- Sumitomo Pharma America, Inc.
Schizophrenia, Schizoaffective Disorder
Prebiotic Treatment in People With Schizophrenia - Pilot Study
The purpose of this study is to examine changes in serum butyrate levels with the prebiotic: Prebiotin (12g/day), an oligofructose-enriched inulin (OEI); the effect of OEI on the composition of the gastrointestinal microbiota in…
- Trial name
- preFOCIS (NCT03617783)
- Testing
- Prebiotin
- Where
- United States
- Volunteers
- 26 people
- Sponsor
- University of Maryland, Baltimore
Schizophrenia, Schizoaffective Disorder
Efficacy Study of Early Onset of Antipsychotic Drug Action in Schizophrenia
The current study has been designed to address the significance of early onset of response prospectively in patients treated with an atypical antipsychotic.
- Conditions
- Schizophrenia, Schizoaffective Disorder, Schizophreniform Disorder
- Trial name
- NCT00337662
- Testing
- olanzapine, risperidone
- Where
- 34 sites in United States, Argentina and 1 more
- Volunteers
- 628 people
- Sponsor
- Eli Lilly and Company
Schizophrenia, Schizoaffective Disorder
Comparing the Effect of Under the Tongue Olanzapine Versus Swallowed Olanzapine on Body Mass Index (A Ratio of Weight to Height)
This study is testing if under the tongue olanzapine for schizophrenia, related psychosis, schizoaffective disorder or bipolar disorder will have less weight gain than olanzapine that is swallowed, in patients who are already…
- Conditions
- Schizophrenia, Schizoaffective Disorder, Bipolar Disorder
- Trial name
- NCT00303602
- Testing
- Sublingual orally disintegrating olanzapine (SODO), Oral olanzapine
- Where
- 21 sites in United States, Canada and 3 more
- Volunteers
- 149 people
- Sponsor
- Eli Lilly and Company
Psychotic Disorders, Schizoaffective Disorder
Functional Rehabilitation of Older Patients With Schizophrenia
The primary purpose of this project is to evaluate the efficacy of a group therapy intervention, cognitive behavioral social skills training (CBSST), that teaches social functioning skills and cognitive-behavioral compensatory…
- Conditions
- Psychotic Disorders, Schizoaffective Disorder, Schizophrenia
- Trial name
- NCT00237796
- Testing
- Cognitive Behavioral Social Skills Training (CBSST), Goal Focused Supportive Contact (GFSC)
- Where
- United States
- Volunteers
- 116 people
- Sponsor
- US Department of Veterans Affairs
Schizophrenia, Schizoaffective Disorder
A Study of Subjects Switched to Lurasidone for the Treatment of Schizophrenia or Schizoaffective Disorder
Lurasidone (lurasidone HCl) is a novel psychotropic agent that is being developed as a potential new antipsychotic treatment for patients with schizophrenia.
- Trial name
- Switch Ext (NCT01143090)
- Testing
- Lurasidone HCl
- Where
- 27 sites in United States
- Volunteers
- 149 people
- Sponsor
- Sumitomo Pharma America, Inc.
Schizophrenia, Psychotic Disorders
Effectiveness of Pimozide in Augmenting the Effects of Clozapine in the Treatment of Schizophrenia
This study will assess the effectiveness of pimozide in enhancing the effects of clozapine in the treatment of schizophrenia.
- Trial name
- NCT00158223
- Testing
- Pimozide
- Where
- 3 sites in United States
- Volunteers
- 76 people
- Sponsor
- Icahn School of Medicine at Mount Sinai
Schizophrenia, Schizoaffective Disorder
Biomarkers in Schizophrenia
N-methyl-D-aspartate (NMDA)-type glutamate receptors are thought to play a pivotal role in neurocognitive dysfunction associated with schizophrenia.
- Trial name
- NCT00817336
- Testing
- D Serine
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- Nathan Kline Institute for Psychiatric Research
Schizophrenia
Comparison of Aripiprazole and Risperidone for the Treatment of People With First-Episode Psychosis
This 52 week long study evaluates the effectiveness of aripiprazole versus risperidone in treating people with first-episode schizophrenia.
- Trial name
- NCT00320671
- Testing
- Aripiprazole, Risperidone
- Where
- United States
- Volunteers
- 198 people
- Sponsor
- Northwell Health
Schizophrenia, Schizoaffective Disorder
Study of Lurasidone in Treating Antipsychotic Naive or Quasi-Naive Children and Adolescents
The overarching purpose of this pilot study is to collect preliminary data regarding the variability of weight gain associated with lurasidone (Latuda©) treatment of antipsychotic naive children and adolescents in order to inform…
- Conditions
- Schizophrenia, Schizoaffective Disorder, Schizophreniform Disorder, Psychosis NOS
- Trial name
- NCT01731119
- Testing
- Latuda©
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- University of North Carolina, Chapel Hill
Smoking Cessation
Novel Smoking Cessation Drug for Schizophrenia
The investigators will evaluate effects of a novel drug that improves nicotinergic receptor function vs. placebo on short-term smoking abstinence in smokers with schizophrenia who have a high interest in quitting.
- Trial name
- TRENDS (NCT02230384)
- Testing
- Active JNJ Drug
- Where
- United States
- Volunteers
- 62 people
- Sponsor
- K.N. Roy Chengappa
Schizophrenic Disorders, Schizoaffective Disorder
Open-Label Study of Intramuscular Olanzapine Depot in Patients With Schizophrenia or Schizoaffective Disorder
This is a long-term, open-label clinical study designed to enable longer-term treatment of patients completing other clinical studies with intramuscular olanzapine depot.
- Trial name
- NCT00088465
- Testing
- Intramuscular olanzapine depot
- Where
- 92 sites in United States, Argentina and 23 more
- Volunteers
- 931 people
- Sponsor
- Eli Lilly and Company
Schizophrenia, Schizoaffective Disorder
Motivation and Skills Support (MASS)
Social impairment contributes to more severe symptoms, higher rates of hospitalization, and increased disability in persons with schizophrenia.
- Trial name
- NCT03404219
- Testing
- Motivation and Skills Support (MASS)
- Where
- 2 sites in United States
- Volunteers
- 31 people
- Sponsor
- Boston University Charles River Campus